Phaseline

Targets › ABL1

ABL1 (Tyrosine-protein kinase ABL1): drug programs, companies and trials

31 programs from 27 companies in 144 trials: 90 Phase 2, 35 Phase 1, 17 Phase 3, 2 Phase 4; Oncology, Other, Neurology; next expected readout Nov 2026.

Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch…. (UniProt, P00519)

Open in Phaseline: the race on ABL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisAsciminib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 4Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase …Sep 2027
National Cancer Institute (NCI)Dasatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia …Jan 2027
Ascentage Pharma GroupOlverembatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic …Mar 2027
Il-Yang Pharm.Radotinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Chronic Myeloid Leukemia, Chronic Phase; Parkinson DiseaseApr 2027
TakedaPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive …Jul 2027
Amsterdam UMC, location VUmcSaracatinib (AZD0530)
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor
ABL1, SRCPhase 2Fibrodysplasia Ossificans ProgressivaNov 2026
National Cancer Institute (NCI)Umbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Grade 1 Follicular LymphomaJan 2027
National Cancer Institute (NCI)Imatinib Mesylate
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 2Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure SyndromeMar 2027
National Cancer Institute (NCI)Nilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Neoplasms; Metastatic Malignant Solid NeoplasmApr 2027
City of Hope Medical CenterUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Mantle Cell LymphomaJul 2027
The Netherlands Cancer InstituteNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2CancerSep 2027
European LeukemiaNetnilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid LeukemiaSep 2027
M.D. Anderson Cancer CenterDasatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Phase Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Advanced Malignant Solid NeoplasmOct 2027
Jennifer R. Brown, MD, PhDUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Chronic Lymphocytic LeukemiaJan 2028
Centre Leon BerardNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Malignant Solid NeoplasmsJan 2028
BayerRegorafenib (BAY73)
Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor
ABL1, RAF1, KIT, FGFR1, MAPK11Phase 2Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic …Apr 2028
ECOG-ACRIN Cancer Research GroupNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAug 2028
Baylor College of MedicineBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Baylor College of MedicineNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Ruijin HospitalAvastinib
BCR-ABL and SRC family kinase inhibitor
ABL1, SRCPhase 2AMLMar 2030
H. Lee Moffitt Cancer Center and Research InstituteBCR-ABL Tyrosine Kinase Inhibitor (TKI)
BCR-ABL inhibitor
ABL1Phase 2Chronic Phase Chronic Myeloid Leukemia–
Masaryk UniversityNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid Leukemia, Chronic Phase–
OtsukaPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid Leukemia–
Taiho PharmaceuticalImatinib
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 1Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic …Dec 2026
Enliven TherapeuticsELVN-001
Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation
BCR, ABL1Phase 1Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia)Dec 2027
University of ChicagoUmbralisib (TGR-1202)
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 1CLLDec 2027
Incyte Biosciences International SàrlPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 1Acute Myeloid LeukemiaFeb 2028
Rina PlattnerNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 1Metastatic MelanomaJul 2028
Children's Oncology GroupBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 1Philadelphia Chromosome Positive CMLJul 2028
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)MK-4208 (TERN-701)
ABL kinase inhibitor
BCR, ABL1Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNov 2029
National Jewish HealthSaracatinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor
ABL1, SRCPhase 1Idiopathic Pulmonary Fibrosis (IPF)–

Conditions

Chronic Myeloid Leukemia (10) Chronic Myeloid Leukemia, Chronic Phase (6) Acute Lymphoblastic Leukemia (5) Gastrointestinal Stromal Tumors (5) Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (3) Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) Hepatocellular Carcinoma (3) Philadelphia Chromosome Positive CML (2) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2) Chronic Myelogenous Leukemia (2) Chronic Myeloid Leukemia (CML) (2)

Modalities

small molecule (15), mixed (13), other (3)

Companies

National Cancer Institute (NCI) (4) Baylor College of Medicine (2) Ascentage Pharma Group (1) Il-Yang Pharm. (1) City of Hope Medical Center (1) Takeda (1) Incyte Biosciences International Sàrl (1) Enliven Therapeutics (1) Novartis (1) M.D. Anderson Cancer Center (1) Jennifer R. Brown, MD, PhD (1) Ruijin Hospital (1) Bayer (1) Amsterdam UMC, location VUmc (1) Taiho Pharmaceutical (1) Masaryk University (1) ECOG-ACRIN Cancer Research Group (1) Rina Plattner (1) European LeukemiaNet (1) The Netherlands Cancer Institute (1)

Related targets

BCR (22) SRC (5) PIK3CD (4) CSNK1E (4) KIT (3) HCK (2) LYN (2) PDGFRB (2) RAF1 (1) FGFR1 (1) MAPK11 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.